Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ:LQDA) (Liquidia or the Company) announced that the PTAB has reaffirmed its original decision in the ‘793 IPR, which found all claims of the ‘793 patent to be unpatentable due to the existence of known prior art cited by Liquidia. In denying UTHR’s request for a rehearing and for a reconsideration of the PTAB’s decision in the ‘793 IPR, the PTAB clarified that the publications cited by Liquidia constituted prior art due to public distribution at large medical conferences more than a year before the filing of the initial patent application that led to the issuance of the ‘793 patent.
Related news for (LQDA)
- Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
- U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
- Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
- District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia